Phil Garner’s Post

Kimberly Westrich (Chief Strategy Officer, National Pharmaceutical Council) shares her highlights in US healthcare value and access from July and August 2024. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #hta #healthtechnologyassessment #healthdata #healthpolicy #valueassessment #inflationreductionact

Want to know what's happened in US healthcare value and access over the past couple of months? Discover recent developments in the latest guest column from Kimberly Westrich of the National Pharmaceutical Council. Read here >>> https://lnkd.in/etEAr4Z5 #healtheconomics #valueassessment #inflationreductionact #QALY #HTA #healthtechnologyassessment

Check out my latest column on The Evidence Base® for recent developments in the intersection of Medicare drug price negotiation and value assessment. Read here >>> https://lnkd.in/etEAr4Z5 #inflationreductionact #hta #valueassessment #qaly

Did you know? 🚨 NHS waiting lists have nearly tripled over the past decade, reaching a staggering 7.4 million patients in England alone! 😱 This surge has created significant challenges for pharmaceutical companies in ensuring patient access to medicines across the UK. 💊 At Apodi, we’ve delved into these issues and provided invaluable insights on how pharmaceutical companies can support the NHS in addressing these waiting lists, while improving access to essential medications. ⚕️ Curious about our findings and how we’re making a difference? Dive into our case study here 👉 https://lnkd.in/edpKraa9 #Healthcare #PatientAccess #PatientCare #PatientExperience #PatientCentricity #PatientSupport #Homecare #PSP #NHS

As the first round of MFP negotiations approach their conclusions this summer a next round of negotiations await with payers who will be armed with public knowledge of MFP levels. How will this impact contracting for MFP-negotiated products and for their competitors? Learn about our perspective on this emerging topic here:

We continue to help clients navigate the complexities surrounding the #InflationReductionAct. Today, our experts are diving into the anticipated effects of the IRA on payer contracting. While the Inflation Reduction Act will lower costs for CMS and patients, it is also likely to cause a range of second-order effects on the pharmaceutical industry, primarily around R&D investments and payer contract dynamics. How should the pharmaceutical industry be preparing for these shifts? Learn more from Thomas Marder, Matthew Riordan, and Scott Briggs in our latest piece here: https://lnkd.in/eXZMa5Xe #Pharma #IRA #Healthcare #Payers

It is here, and it is real. The #inflationreductionact, learn more how to navigate the various complex dynamics from our experts, Scott Briggs, Thomas Marder, Matthew Riordan

As goes the U.S, so go the rest of the world! All of us are watching how the pharma pricing scenarios will play out with the U.S. IRA. Check out my colleagues' viewpoints here...

On August 15, 2024, the Centers for Medicare & Medicaid Services (CMS) announced the results of the first round of Medicare drug price negotiations under the Inflation Reduction Act (#IRA). The negotiated prices for 10 selected Part D drugs are expected to yield significant savings, with an estimated $6 billion reduction in net covered prescription drug costs and a 22% lower net spend in aggregate. Most drugs will now be sold at a 65-80% discount off list price. While this announcement provides some clarity on immediate financial impacts, many questions remain about the long-term implications for the pharmaceutical industry, drug development, and patient access to innovative therapies. In their recent #ExecutiveInsights, my colleagues Alex Guth and Adam Nover discuss the announcement and break down both what was clarified and what remains uncertain: https://lnkd.in/dV2x6Tcv #lekconsulting #lek

Medunik USA, member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its Global Hypergrowth Project, is pleased to share that coverage for its rare disease product continues expanding with four more states adding it to their Medicaid Preferred Drug Lists. Pheburane® is now covered under Medicaid program in 10 states, namely Georgia, Indiana, Missouri, New Hampshire, New Mexico*, North Dakota, Oklahoma, Tennessee, Texas, Utah*. Pheburane® is also included on the Contract Drugs List in California. With the continued favorable commercial and Medicaid coverage updates, Pheburane® is reaching more patients all over the USA while being recognized as a first-line therapy by health authorities in key states.   *Certain Managed Medicaid plans More information in the press release: https://lnkd.in/etuBnimG To learn more about Medunik USA: https://lnkd.in/e2jYnwzt To learn more about Duchesnay Pharmaceutical Group: https://lnkd.in/efxzPy-D Full Prescribing Information: https://lnkd.in/eBsBfVB8 #UCD #orphandrugs #raredisease